spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  protein degradation 

 HSMN NewsFeed - 24 Aug 2022
Plexium Strengthens Leadership Team with Appointment of Daniel Sipes as Senior Vice President, Head of Technology
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Aug 2022
Biotheryx Announces Appointment of Tracy Lawhon as Chief Development Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Jun 2022
Degron Therapeutics Raises $22M Series A Financing to Accelerate Growth and Expand Molecular-Glue-Based Targeted Protein Degradation Drug Discovery Platform
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 23 Feb 2022
Plexium Announces $102M Financing To Advance Pipeline Of Targeted Protein Degradation Therapies And Technology Platform
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 20 Jan 2022
BioTheryX Announces Appointment of Sahm Nasseri as Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Dec 2021
Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn's Proprietary Gene Traffic Control(R) Platform
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Oct 2021
BioTheryX Announces Appointment of Philippe Drouet as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Sep 2021
Obsidian Therapeutics Announces Closing of $115 Million Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 20 May 2021
BioTheryX Announces $92M Series E Financing to Accelerate Development of Targeted Protein Degradation Pipeline and Technology Platform in Oncology
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 2 Dec 2020
AbbVie and Frontier Medicines Establish Global Partnership to Discover and Develop Novel Therapies and E3 Degraders Against Difficult-to-Drug Targets
Biopharmaceuticals
 HSMN NewsFeed - 20 Nov 2019
Kymera Therapeutics Promotes Nello Mainolfi, PhD, to Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Sep 2019
BioTheryX, Inc. Announces the Appointment of Biopharma Veteran Jeffrey L. Edwards to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 15 Jul 2019
Kymera Therapeutics Announces Leadership Transitions
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Apr 2019
Vividion Therapeutics Announces Oversubscribed $82 Million Series B Financing
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 13 Nov 2018
Kymera Therapeutics Announces $65 Million Series B Financing to Advance Pipeline of Targeted Protein Degraders in Oncology and Immunology
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 20 Sep 2018
Dr. Jared Gollob Joins Kymera Therapeutics as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Apr 2018
Arvinas Completes $55 Million Series C Financing to Advance Protein Degradation Platform
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 30 Oct 2017
Kymera Therapeutics Announces Series A to Advance Novel Therapeutic Modality and Develop Innovative Therapies
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 20 Sep 2017
Arvinas Appoints Dr. John Houston as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Jul 2017
Kezar Life Sciences Announces Successful Completion of Phase 1a Study and Secures $50 Million in Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 7 Jan 2016
C4 Therapeutics Enters Strategic Drug Discovery Collaboration in the Promising New Field of Targeted Protein Degradation
Biopharmaceuticals
 HSMN NewsFeed - 7 Jan 2016
C4 Therapeutics Launches with $73 Million Series A Financing
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 21 Oct 2015
Arvinas Secures $41.6M Series B Financing - Appoints New Board Members
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 16 Jun 2015
Kezar Life Sciences Closes $23M Series A Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 22 May 2014
Third Rock Ventures and The Column Group Launch Nurix with $25.1 Million Financing to Target Key Regulatory Pathway
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 11 Feb 2014
Arvinas Hires Jim Winkler as Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Apr 2013
Cleave Biosciences Adds New Investor and $10 Million to Series A Financing
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 11 Oct 2011
Cleave Biosciences Raises $42 Million in Series A Financing for Novel Cancer Therapies
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 12 Oct 2009
Proteolix, Inc. to be Acquired By Onyx Pharmaceuticals
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 12 Oct 2009
Onyx Pharmaceuticals to Acquire Proteolix, Inc.
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 25 Feb 2009
Proteolix Announces the Appointment of John Scarlett, M.D., President and CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Sep 2008
Proteolix Raises $79 Million in Series C Financing
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 1 Jul 2008
Repligen Elects Alfred L. Goldberg, Ph.D. to the Board of Directors
Biopharmaceuticals Personnel
Return to NewsFeed  

 Additional items found! 2

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 2 additional stories matching:
protein degradation
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.